GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Huadong Medicine Co 000963.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

27.05

-2.42%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥43.61bn

FY2016FY2025

Net income

CN¥3.41bn

FY2016FY2025

Free cash flow

CN¥2.67bn

FY2016FY2025

Shareholders' equity

CN¥24.81bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥43.61bnCN¥41.91bnCN¥40.62bnCN¥37.71bnCN¥34.56bnCN¥33.68bnCN¥35.45bnCN¥30.66bnCN¥27.83bnCN¥25.38bn
Gross profitCN¥14.11bnCN¥13.90bnCN¥13.16bnCN¥12.03bnCN¥10.59bnCN¥11.13bnCN¥11.36bnCN¥8.89bnCN¥7.27bnCN¥6.16bn
Research and developmentCN¥1.75bnCN¥1.47bnCN¥1.27bnCN¥1.02bnCN¥979.6mCN¥926.7mCN¥1.07bnCN¥707.3mCN¥461.8mCN¥264.1m
Operating incomeCN¥4.49bnCN¥4.32bnCN¥3.50bnCN¥3.06bnCN¥2.86bnCN¥3.48bnCN¥3.19bnCN¥2.91bnCN¥2.34bnCN¥1.92bn
Net incomeCN¥3.41bnCN¥3.51bnCN¥2.84bnCN¥2.50bnCN¥2.30bnCN¥2.82bnCN¥2.81bnCN¥2.27bnCN¥1.78bnCN¥1.45bn
Diluted earnings per share1.952.011.621.431.321.611.611.301.020.83

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥39.04bnCN¥37.88bnCN¥33.51bnCN¥31.19bnCN¥27.00bnCN¥24.39bnCN¥21.46bnCN¥19.22bnCN¥15.99bnCN¥14.46bn
Cash and short-term investments—CN¥5.28bnCN¥4.68bnCN¥4.03bnCN¥4.03bnCN¥3.20bnCN¥2.40bnCN¥2.44bnCN¥3.19bnCN¥2.81bn
Total liabilitiesCN¥13.87bnCN¥14.32bnCN¥11.93bnCN¥12.02bnCN¥10.06bnCN¥9.21bnCN¥8.60bnCN¥8.79bnCN¥7.18bnCN¥6.81bn
Debt—CN¥3.05bnCN¥2.04bnCN¥2.87bnCN¥2.76bnCN¥2.16bnCN¥2.30bnCN¥2.19bnCN¥1.74bnCN¥1.98bn
Shareholders' equityCN¥24.81bnCN¥23.06bnCN¥21.05bnCN¥18.58bnCN¥16.58bnCN¥14.62bnCN¥12.31bnCN¥9.94bnCN¥8.39bnCN¥7.28bn
Shares outstanding1,754m1,751m1,754m1,750m1,750m1,750m1,750m1,750m1,750m1,752m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥4.25bnCN¥3.75bnCN¥3.93bnCN¥2.38bnCN¥3.17bnCN¥3.41bnCN¥2.00bnCN¥2.04bnCN¥1.66bnCN¥1.35bn
Capital spending−CN¥1.57bn−CN¥1.73bn−CN¥1.61bn−CN¥1.19bn−CN¥819.1m−CN¥1.47bn−CN¥1.35bn−CN¥876.5m−CN¥478.7m−CN¥467.0m
Free cash flowCN¥2.67bnCN¥2.02bnCN¥2.32bnCN¥1.19bnCN¥2.35bnCN¥1.94bnCN¥648.3mCN¥1.16bnCN¥1.18bnCN¥880.0m
Dividends paid−CN¥1.69bn−CN¥1.70bn−CN¥594.2m−CN¥576.5m−CN¥460.1m−CN¥565.7m−CN¥570.6m−CN¥769.2m−CN¥727.3m−CN¥697.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥10.88bnCN¥11.18bnCN¥10.95bnCN¥10.99bnCN¥10.94bnCN¥10.74bnCN¥10.43bnCN¥10.51bn
Gross profitCN¥3.44bnCN¥3.80bnCN¥3.16bnCN¥3.60bnCN¥3.82bnCN¥3.53bnCN¥3.65bnCN¥3.39bn
Operating incomeCN¥1.09bnCN¥1.22bnCN¥923.6mCN¥1.11bnCN¥1.11bnCN¥1.13bnCN¥1.11bnCN¥1.13bn
Net incomeCN¥858.6mCN¥1.00bnCN¥666.4mCN¥933.1mCN¥900.1mCN¥914.7mCN¥949.8mCN¥866.3m
Diluted earnings per share0.490.570.380.530.510.520.540.49
Cash from operations———CN¥155.0mCN¥3.29bn−CN¥832.0mCN¥1.24bnCN¥231.0m
Capital spending−CN¥456.0m−CN¥261.0m−CN¥489.0m−CN¥297.0m−CN¥151.0m−CN¥637.0m−CN¥797.0m−CN¥272.0m
Free cash flow———−CN¥142.0mCN¥3.14bn−CN¥1.47bnCN¥445.0m−CN¥41.0m
Total assetsCN¥39.98bnCN¥39.91bnCN¥39.04bnCN¥39.93bnCN¥38.82bnCN¥39.45bnCN¥37.88bnCN¥37.50bn
Cash and short-term investments———CN¥4.38bnCN¥5.16bnCN¥3.71bnCN¥5.28bnCN¥4.74bn
DebtCN¥250.1mCN¥251.6mCN¥252.0mCN¥5.55bnCN¥2.17bnCN¥2.47bnCN¥2.33bnCN¥1.90bn
Shareholders' equityCN¥25.44bnCN¥25.73bnCN¥24.81bnCN¥24.13bnCN¥23.75bnCN¥24.06bnCN¥23.06bnCN¥22.04bn

Financial ratios

Data as of 15 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin32.4%33.2%32.4%31.9%30.7%33.0%
Operating margin10.3%10.3%8.6%8.1%8.3%10.3%
Net margin7.8%8.4%7.0%6.6%6.7%8.4%
Return on equity13.8%15.2%13.5%13.5%13.9%19.3%
Return on assets8.7%9.3%8.5%8.0%8.5%11.6%
Free cash flow yield12.7%11.9%12.0%7.8%8.7%10.7%
Revenue growth4.1%3.2%7.7%9.1%2.6%-5.0%
Earnings growth-2.8%23.7%13.6%8.6%-18.4%0.2%
Current ratio1.62x1.53x1.71x1.73x1.67x1.68x
Debt to equity0.01x0.10x0.06x0.11x0.08x0.11x
Equity ratio63.6%60.9%62.8%59.6%61.4%60.0%
Interest coverage52.12x34.96x24.27x20.84x28.50x40.83x
R&D as a share of sales4.0%3.5%3.1%2.7%2.8%2.8%
Buybacks as a share of market value-0.2%0.2%-0.3%0.0%0.0%-0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.0%5.3%7.2%
Operating income13.6%5.2%12.5%
Net income11.0%3.9%12.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin32.8%32.5%32.3%30.5%
Operating margin10.3%9.4%9.4%9.0%
Net margin8.1%7.5%7.5%7.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings20.317.325.632.830.616.515.217.029.424.3
Price to sales1.61.41.82.22.01.41.21.31.91.4

Dividends and splits

Per share, in the currency the company pays

Paid for 12 years. Last went ex-dividend on 10 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.580.930.930.290.290.230.280.275
  • 6-for-5 split · 21 Jun 2019
  • 3-for-2 split · 13 Jun 2018
  • 2-for-1 split · 24 May 2017
  • 1-to-1 reverse split · 1 Nov 2006
  • 2-for-1 split · 11 Jul 2002

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.